Are biotech VCs headed for better times? In one firm’s success, lessons for turning crisis into profit
This article is adapted from STAT’s latest report, “2023 Update: ranking biotech’s top venture capital firms.”
Right now, venture capital firms are struggling with the impact of a persistently anemic biotech market. But if past downturns are any indication, some VCs will steer out of the slump into brighter times.
